EP3650025A4 - Pharmazeutische zusammensetzung und verfahren zur herstellung davon - Google Patents

Pharmazeutische zusammensetzung und verfahren zur herstellung davon Download PDF

Info

Publication number
EP3650025A4
EP3650025A4 EP18828577.9A EP18828577A EP3650025A4 EP 3650025 A4 EP3650025 A4 EP 3650025A4 EP 18828577 A EP18828577 A EP 18828577A EP 3650025 A4 EP3650025 A4 EP 3650025A4
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical composition
preparing same
preparing
same
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18828577.9A
Other languages
English (en)
French (fr)
Other versions
EP3650025A1 (de
Inventor
Daimei ZHANG
Tingting Zhang
Huan DING
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of EP3650025A1 publication Critical patent/EP3650025A1/de
Publication of EP3650025A4 publication Critical patent/EP3650025A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP18828577.9A 2017-07-04 2018-07-03 Pharmazeutische zusammensetzung und verfahren zur herstellung davon Pending EP3650025A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710536705 2017-07-04
CN201711105075 2017-11-10
PCT/CN2018/094211 WO2019007317A1 (zh) 2017-07-04 2018-07-03 一种药物组合物及其制备方法

Publications (2)

Publication Number Publication Date
EP3650025A1 EP3650025A1 (de) 2020-05-13
EP3650025A4 true EP3650025A4 (de) 2021-04-28

Family

ID=64950432

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18828577.9A Pending EP3650025A4 (de) 2017-07-04 2018-07-03 Pharmazeutische zusammensetzung und verfahren zur herstellung davon

Country Status (14)

Country Link
US (1) US11304945B2 (de)
EP (1) EP3650025A4 (de)
JP (1) JP7190452B2 (de)
KR (1) KR102697985B1 (de)
CN (1) CN109963565B (de)
AU (1) AU2018296476B2 (de)
BR (1) BR112019027473A2 (de)
CA (1) CA3066046A1 (de)
MX (1) MX2019015612A (de)
RU (1) RU2767872C2 (de)
TW (1) TWI837095B (de)
UA (1) UA127413C2 (de)
WO (1) WO2019007317A1 (de)
ZA (1) ZA201908090B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111499642A (zh) * 2019-01-31 2020-08-07 江苏恒瑞医药股份有限公司 吡咯并[2,3-d]哒嗪-7-酮类衍生物的可药用盐、晶型及其制备方法
TW202100527A (zh) * 2019-05-31 2021-01-01 大陸商江蘇恆瑞醫藥股份有限公司 一種固體分散體及其製備方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016007185A1 (en) * 2014-07-07 2016-01-14 Eternity Bioscience Inc. Aminopyridazinone compounds as protein kinase inhibitors
WO2016145138A1 (en) * 2015-03-10 2016-09-15 Shionogi Inc. Solid dispersions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2619438A1 (en) * 2005-08-29 2007-03-08 Irwin C. Jacobs Amorphous solid dispersions of 7-chloro-n,n, 5-trimethyl-4-oxo-3-phenyl-3, 5,-dihydro-4h-pyridazino(4,5-b) indole-1-acetamide
WO2008138755A2 (en) * 2007-05-11 2008-11-20 F. Hoffmann-La Roche Ag Pharmaceutical compositions for poorly soluble drugs
JP2013103899A (ja) 2011-11-11 2013-05-30 Fuji Chem Ind Co Ltd 難溶性薬物の新規な固体分散体
NZ737725A (en) 2012-06-04 2019-06-28 Pharmacyclics Llc Crystalline forms of a bruton’s tyrosine kinase inhibitor
EA028009B1 (ru) * 2013-01-22 2017-09-29 Ф.Хоффманн-Ля Рош Аг Фармацевтическая композиция с улучшенной биодоступностью
EP3030242A1 (de) * 2013-08-06 2016-06-15 Oncoethix GmbH Verfahren zur behandlung von diffusem grossem b-zell-lymphome (dlbcl) unter verwendung eines bet-bromodomäneninhibitors
KR20170033358A (ko) * 2014-08-07 2017-03-24 파마싸이클릭스 엘엘씨 브루톤 티로신 키나아제 저해제의 신규한 제제

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016007185A1 (en) * 2014-07-07 2016-01-14 Eternity Bioscience Inc. Aminopyridazinone compounds as protein kinase inhibitors
WO2016145138A1 (en) * 2015-03-10 2016-09-15 Shionogi Inc. Solid dispersions

Also Published As

Publication number Publication date
RU2767872C2 (ru) 2022-03-22
AU2018296476A1 (en) 2020-01-16
MX2019015612A (es) 2020-02-26
TWI837095B (zh) 2024-04-01
CN109963565A (zh) 2019-07-02
JP7190452B2 (ja) 2022-12-15
TW201906609A (zh) 2019-02-16
CA3066046A1 (en) 2019-01-10
US20200171031A1 (en) 2020-06-04
KR20200024237A (ko) 2020-03-06
CN109963565B (zh) 2021-09-03
RU2020102280A3 (de) 2021-09-17
BR112019027473A2 (pt) 2020-07-07
JP2020525415A (ja) 2020-08-27
ZA201908090B (en) 2021-08-25
US11304945B2 (en) 2022-04-19
UA127413C2 (uk) 2023-08-16
EP3650025A1 (de) 2020-05-13
AU2018296476B2 (en) 2023-11-02
KR102697985B1 (ko) 2024-08-23
RU2020102280A (ru) 2021-08-04
WO2019007317A1 (zh) 2019-01-10

Similar Documents

Publication Publication Date Title
EP3626803A4 (de) Zusammensetzung und verfahren zur herstellung der zusammensetzung
EP3453707A4 (de) Benzazepinderivat, herstellungsverfahren, pharmazeutische zusammensetzung und verwendung davon
EP3351242A4 (de) Cannabinoidhaltige orale pharmazeutische zusammensetzung, verfahren zur herstellung und verwendung davon
EP3312177A4 (de) Tricyclische derivatverbindung, herstellungsverfahren dafür und pharmazeutische zusammensetzung damit
EP3486242A4 (de) Oxopicolinamid-derivat, herstellungsverfahren dafür und pharmazeutische verwendung davon
EP3328562A4 (de) Clean-in-place-verfahren, system und zusammensetzung dafür
EP3130354A4 (de) Pharmazeutische posaconazolzusammensetzung und herstellungsverfahren, anwendung und pharmazeutisches präparat davon
EP3704227A4 (de) Zusammensetzung und verfahren
EP3733650A4 (de) Verfahren zur herstellung eines elagolix-zwischenprodukts und zusammensetzung davon
EP3587375A4 (de) Betonzusammensetzung und verfahren zur herstellung davon
EP3438105A4 (de) Diaryl-beta-lactam-verbindung und herstellungsverfahren und pharmazeutische verwendung davon
EP3604470A4 (de) Haftzusammensetzung und verfahren zur herstellung davon
EP3670511A4 (de) Tetrahydroprotoberberinverbindung, verfahren zu ihrer herstellung und ihre verwendung sowie pharmazeutische zusammensetzung
EP3590361A4 (de) Luteolinhaltige zusammensetzung und verfahren zur herstellung davon
EP3653202A4 (de) Pharmazeutische zubereitung und herstellungsverfahren dafür
EP3181553A4 (de) Quinazolinderivat, herstellungsverfahren dafür und pharmazeutische zusammensetzung sowie verwendung davon
EP3626686A4 (de) Zusammensetzung für glas, glas, herstellungsverfahren und anwendung davon
EP3404024A4 (de) Chinazolinderivat, herstellungsverfahren dafür, pharmazeutische zusammensetzung und anwendungen
EP3450450A4 (de) Vancomycin-derivat, herstellungsverfahren, pharmazeutische zusammensetzung und verwendung davon
EP3398615A4 (de) Mucoadhäsive pharmazeutische zusammensetzung und herstellungsverfahren dafür
EP3388433A4 (de) Phthalazinderivate und herstellungsverfahren, pharmazeutische zusammensetzung und verwendung davon
EP3632911A4 (de) Verfahren zur herstellung einer isoxazinonverbindung und anwendung davon
EP3303320A4 (de) Neuartige heterocyclische verbindung, verfahren zur herstellung davon und pharmazeutische zusammensetzung damit
EP3284743A4 (de) Verbindungen mit heterocyclischem imidazol, pharmazeutische zusammensetzungen daraus, herstellungsverfahren dafür und verwendung davon
EP3424521A4 (de) Pharmazeutische zusammensetzung und herstellungsverfahren dafür

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200122

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031500000

Ipc: A61K0009140000

A4 Supplementary search report drawn up and despatched

Effective date: 20210325

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/14 20060101AFI20210319BHEP

Ipc: A61K 9/20 20060101ALI20210319BHEP

Ipc: A61K 31/5025 20060101ALI20210319BHEP

Ipc: A61K 9/26 20060101ALI20210319BHEP

Ipc: A61P 19/02 20060101ALI20210319BHEP

Ipc: A61P 35/00 20060101ALI20210319BHEP

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.